المؤلفون: Cardona-Hernandez, Roque, Dôvc, Klemen, Biester, Torben, Macedoni, Maddalena, Tauschmann, Martin, Mameli, Chiara, Ekhlaspour, Laya

مصطلحات موضوعية: Automated insulin delivery, Children, Technology, Time in range, Type 1 diabetes, Youths, Young Adult, Humans, Adolescent, Child, Adult, Diabetes Mellitus, Type 1, Hypoglycemic Agents, Glycemic Control, Blood Glucose Self-Monitoring, Blood Glucose, Insulin, Insulin Infusion Systems

الوصف: Type 1 diabetes (T1D) is the most frequent form of diabetes in pediatric age, affecting more than 1.5 million people younger than age 20 years worldwide. Early and intensive control of diabetes provides continued protection against both microvascular and macrovascular complications, enhances growth, and ensures normal pubertal development. In the absence of definitive reversal therapy for this disease, achieving and maintaining the recommended glycemic targets is crucial. In the last 30 years, enormous progress has been made using technology to better treat T1D. In spite of this progress, the majority of children, adolescents and young adults do not reach the recommended targets for glycemic control and assume a considerable burden each day. The development of promising new therapeutic advances, such as more physiologic insulin analogues, pioneering diabetes technology including continuous glucose monitoring and closed loop systems as well as new adjuvant drugs, anticipate a new paradigm in T1D management over the next few years. This review presents insights into current management of T1D in youths.

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/7s31w37tTest

المؤلفون: Stefano Zucchini, Stefano Tumini, Andrea Enzo Scaramuzza, Riccardo Bonfanti, Maurizio Delvecchio, Roberto Franceschi, Dario Iafusco, Lorenzo Lenzi, Enza Mozzillo, Stefano Passanisi, Claudia Piona, Ivana Rabbone, Novella Rapini, Andrea Rigamonti, Carlo Ripoli, Giuseppina Salzano, Silvia Savastio, Riccardo Schiaffini, Angela Zanfardino, Valentino Cherubini, Diabetes Study Group of the Italian Society for Pediatric Endocrinology Diabetes, Albino Claudia Accursia, Aloe Monica, Anzelotti Maria Teresa, Arnaldi Claudia, Barbetti Fabrizio, Bassi Marta, Berioli Maria Giulia, Bernardini Luca, Bertelli Enrica, Biagioni Martina, Bobbio Adriana, Bombaci Bruno, Bonfanti Riccardo, Bonura Clara, Bracciolini Giulia Patrizia, Bruzzese Mariella, Bruzzi Patrizia, Buono Pietro, Buscarino Piera, Cadario Francesco, Calcaterra Valeria, Calzi Elena, Cappa Marco, Cardani Roberta, Cardella Francesca, Cardinale Giuliana Marcella, Casertano Alberto, Castorani Valeria, Cauvin Vittoria, Cenciarelli Valentina, Ceruti Franco, Cherubini Valentino, Chiarelli Francesco, Chiari Giovanni, Cianfarani Stefano, Cicchetti Mario, Cipriano Paola, Cirillo Dante, Citriniti Felice, Coccioli Maria Susanna, Confetto Santino, Contreas Giovanna, Coro Anna, Correddu Antonella, Corsini Elisa, Crino’ Antonino, d’Annunzio Giuseppe, De Berardinis Fiorella, De Donno Valeria, De Filippo Gianpaolo, De Marco Rosaria, De Sanctis Luisa, Del Duca Elisabetta, Delvecchio Maurizio, Deodati Annalisa, Di Bonito Procolo, Di Candia Francesca, Faleschini Elena, Fattorusso Valentina, Favia Anna, Federico Giovanni, Felappi Barbara, Ferrari Mara, Ferrito Lucia, Fichera Graziella, Fontana Franco, Fornari Elena, Franceschi Roberto, Franco Francesca, Franzese Adriana, Frongia Anna Paola, Frontino Giulio, Gaiero Alberto, Galassi Sabrina Maria, Gallo Francesco, Gargantini Luigi, Giani Elisa, Gortan Anna Jolanda, Graziani Vanna, Grosso Caterina, Gualtieri Antonella, Guasti Monica, Guerraggio Lucia Paola, Guzzetti Chiara, Iafusco Dario, Iannicelli Gennaro, Iezzi Maria Laura, Ignaccolo Maria Giovanna, Innaurato Stefania, Inzaghi Elena, Iovane Brunella, Iughetti Lorenzo, Kaufmann Peter, La Loggia Alfonso, Lambertini Anna Giulia, Lapolla Rosa, Lasagni Anna, Lazzaro Nicola, Lazzeroni Pietro, Lenzi Lorenzo, Lera Riccardo, Levantini Gabriella, Lezzi Marilea, Lia Rosanna, Liguori Alice, Lo Presti Donatella, Lombardo Fortunato, Lonero Antonella, Longhi Silvia, Lorubbio Antonella, Lucchesi Sonia, Maccioni Rosella, Macedoni Maddalena, Macellaro Patrizia Cristiana, Madeo Simona Filomena, Maffeis Claudio, Mainetti Benedetta, Maltoni Giulio, Mameli Chiara, Mammì Francesco, Manca Bitti Maria Luisa, Mancioppi Valentina, Manco Melania, Marigliano Marco, Marino Monica, Marsciani Alberto, Matteoli Maria Cristina, Mazzali Elena, Minute Marta, Minuto Nicola, Monti Sara, Morandi Anita,, Morganti Gianfranco, Morotti Elisa, Mozzillo Enza, Musolino Gianluca, Olivieri Francesca, Ortolani Federica, Pampanini Valentina, Pardi Daniela, Pascarella Filomena, Pasquino Bruno, Passanisi Stefano, Patera Ippolita Patrizia, Pedini Annalisa, Pennati Maria Cristina, Peruzzi Sonia, Peverelli Paola, Pezzino Giulia, Piccini Barbara, Piccinno Elvira Eugenia Rosaria, Piona Claudia, Piredda Gavina, Piscopo Alessia, Pistone Carmelo, Pozzi Erica, Prandi Elena, Predieri Barbara, Prudente Sabrina, Pulcina Anna, Rabbone Ivana, Randazzo Emioli, Rapini Novella, Reinstadler Petra, Riboni Sara, Ricciardi Maria Rossella, Rigamonti Andrea, Ripoli Carlo, Rossi Virginia, Rossi Paolo, Rutigliano Irene, Sabbion Alberto, Salvatoni Alessandro, Salvo Caterina, Salzano Giuseppina, Sanseviero Mariateresa, Savastio Silvia, Savini Rosanna, Scanu Mariapiera, Scaramuzza Andrea Enzo, Schiaffini Riccardo, Schiavone Maurizio, Schieven Eleonardo, Scipione Mirella, Secco Andrea, Silvestri Francesca, Siri Giulia, Sogno Valin Paola, Sordelli Silvia, Spiri Daniele, Stagi Stefano, Stamati Filomena Andreina, Suprani Tosca, Talarico Valentina, Tiberi Valentina, Timpanaro Tiziana Antonia Lucia, Tinti Davide, Tirendi Antonina, Tomaselli Letizia Grazia, Toni Sonia, Torelli Cataldo, Tornese Gianluca, Trada Michela,, Trettene Adolfo Andrea, Tumini Stefano, Tumminelli Marilena, Valerio Giuliana, Vandelli Sara, Ventrici Claudia, Zampolli Maria, Zanatta Manuela, Zanfardino Angela, Zecchino Clara, Zonca Silvia, Zucchini Stefano

المصدر: Frontiers in Endocrinology, Vol 15 (2024)

مصطلحات موضوعية: adolescents, automated insulin delivery, children, hypoglycemia, glucagon, oral glucose, Diseases of the endocrine glands. Clinical endocrinology, RC648-665

الوصف: There has been continuous progress in diabetes management over the last few decades, not least due to the widespread dissemination of continuous glucose monitoring (CGM) and automated insulin delivery systems. These technological advances have radically changed the daily lives of people living with diabetes, improving the quality of life of both children and their families. Despite this, hypoglycemia remains the primary side-effect of insulin therapy. Based on a systematic review of the available scientific evidence, this paper aims to provide evidence-based recommendations for recognizing, risk stratifying, treating, and managing patients with hypoglycemia. The objective of these recommendations is to unify the behavior of pediatric diabetologists with respect to the timely recognition and prevention of hypoglycemic episodes and the correct treatment of hypoglycemia, especially in patients using CGM or advanced hybrid closed-loop systems. All authors have long experience in the specialty and are members of the Italian Society of Pediatric Endocrinology and Diabetology. The goal of treating hypoglycemia is to raise blood glucose above 70 mg/dL (3.9 mmol/L) and to prevent further decreases. Oral glucose at a dose of 0.3 g/kg (0.1 g/kg for children using “smart pumps” or hybrid closed loop systems in automated mode) is the preferred treatment for the conscious individual with blood glucose

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fendo.2024.1387537/fullTest; https://doaj.org/toc/1664-2392Test

الوصول الحر: https://doaj.org/article/04c5d7ea5bbf4c18b2fce4857d7be15dTest

المؤلفون: Cherubini, Valentino, Fargalli, Andrea, Arnaldi, Claudia, Bassi, Marta, Bonfanti, Riccardo, Patrizia Bracciolini, Giulia, Cardella, Francesca, Dal Bo, Sara, Delvecchio, Maurizio, Di Candia, Francesca, Franceschi, Roberto, Maria Galassi, Sabrina, Gallo, Francesco, Graziani, Vanna, Iannilli, Antonio, Mameli, Chiara, Marigliano, Marco, Minuto, Nicola, Monti, Sara, Mozzillo, Enza, Pascarella, Filomena, Predieri, Barbara, Rabbone, Ivana, Roppolo, Rosalia, Schiaffini, Riccardo, Tiberi, Valentina, Tinti, Davide, Toni, Sonia, Scaramuzza, Andrea, Vestrucci, Benedetta, Gesuita, Rosaria

المساهمون: Cherubini, Valentino, Fargalli, Andrea, Arnaldi, Claudia, Bassi, Marta, Bonfanti, Riccardo, Patrizia Bracciolini, Giulia, Cardella, Francesca, Dal Bo, Sara, Delvecchio, Maurizio, Di Candia, Francesca, Franceschi, Roberto, Maria Galassi, Sabrina, Gallo, Francesco, Graziani, Vanna, Iannilli, Antonio, Mameli, Chiara, Marigliano, Marco, Minuto, Nicola, Monti, Sara, Mozzillo, Enza, Pascarella, Filomena, Predieri, Barbara, Rabbone, Ivana, Roppolo, Rosalia, Schiaffini, Riccardo, Tiberi, Valentina, Tinti, Davide, Toni, Sonia, Scaramuzza, Andrea, Vestrucci, Benedetta, Gesuita, Rosaria

مصطلحات موضوعية: Children and adolescent, DIDS, Diabetes technology, Health related quality of life, Treatment modalitie, Type 1 diabetes

الوصف: Aims: To analyze metabolic outcomes, diabetes impact and device satisfaction in children and adolescents with type 1 diabetes in Italy who used different treatment modalities for diabetes care in a real-life context. Methods: In this multicenter, nationwide, cross-sectional study, 1464 participants were enrolled at a routine visit. The following treatment modalities were considered MDI+SMBG; MDI+CGM; Sensor Augmented Pump Therapy; predictive management of low glucose; Hybrid Closed Loop (HCL); Advanced Hybrid Closed Loop (AHCL). Health related quality of life was evaluated by the Italian version of the Diabetes Impact and Device Satisfaction Scale (DIDS) questionnaire. Results: Patients treated with AID systems were more likely to have HbA1c≤6.5%, higher percentage of time with glucose levels between 70 and 180mg/dL, lower percentage of time with glucose levels above 180mg/dL, higher device satisfaction, and reduced impact of diabetes. All the therapeutic modalities with respect to MDI+CGM, except for MDI+SMBG, contributed to increase the device satisfaction. HCL and AHCL respect to MDI+CGM were associated with lower diabetes impact. Conclusion: Real-life use of automated insulin delivery systems is associated with reduced type 1 diabetes impact, increased device satisfaction, and achievement of glycemic goals.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/38499182; volume:210; firstpage:1; lastpage:8; journal:DIABETES RESEARCH AND CLINICAL PRACTICE; https://hdl.handle.net/11380/1335406Test

الإتاحة: https://doi.org/10.1016/j.diabres.2024.111621Test
https://hdl.handle.net/11380/1335406Test

المؤلفون: Mameli, Chiara, Guadagni, Liliana, Orso, Massimiliano, Calcaterra, Valeria, Wasniewska, Malgorzata Gabriela, Aversa, Tommaso, Granato, Simona, Bruschini, Pietro, d'Angela, Daniela, Spandonaro, Federico, Polistena, Barbara, Zuccotti, Gianvincenzo

المساهمون: C. Mameli, L. Guadagni, M. Orso, V. Calcaterra, M.G. Wasniewska, T. Aversa, S. Granato, P. Bruschini, D. D'Angela, F. Spandonaro, B. Polistena, G. Zuccotti

مصطلحات موضوعية: Epidemiology, GHD, Growth hormone deficiency, Incidence, Prevalence, Settore MED/38 - Pediatria Generale e Specialistica

الوصف: ObjectiveGrowth hormone deficiency (GHD) is the most common pituitary hormone deficiency and is one of the main causes of short stature in children and adolescents. The aim of this study is to evaluate the epidemiology of pediatric GHD worldwide, since no other systematic review has been published so far.MethodsWe searched PubMed, Embase, and Web of Science up to July 2023 to find epidemiological studies involving children with GHD. Two review authors independently screened articles, extracted data and performed the quality assessment.ResultsWe selected 9 epidemiological studies published from 1974 to 2022. The range of prevalence was 1/1107-1/8,646. A study based on a registry of GH users in the Piedmont region (Italy) reported the highest mean prevalence. In the included studies, the mean incidence ranged from 1/28,800 to 1/46,700 cases per year. One study reported a 20-year cumulative incidence of 127/100,000 for boys and 93/100,000 for girls. Studies were heterogeneous in terms of population (age and GHD etiology) and diagnostic criteria. As for the methodological quality of included studies, all but one study satisfied the majority of the checklist items.ConclusionsThe included studies are mostly European, so the provided estimates cannot be considered global. International multicentre studies are needed to compare epidemiological estimates of GHD among different ethnical groups. Considering the considerable cost of human recombinant GH, the only available therapy to treat GHD, understanding accurate epidemiological estimates of GHD in each country is fundamental for resource allocation.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/38498128; info:eu-repo/semantics/altIdentifier/wos/WOS:001186393000002; firstpage:1; lastpage:8; numberofpages:8; journal:ENDOCRINE; https://hdl.handle.net/2434/1043689Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85187948725

الإتاحة: https://doi.org/10.1007/s12020-024-03778-4Test
https://hdl.handle.net/2434/1043689Test

المؤلفون: Cassio, Alessandra, Marescotti, Gloria, Aversa, Tommaso, Salerno, Mariacarolina, Tornese, Gianluca, Stancampiano, Marianna, Tuli, Gerdi, Faienza, Maria Felicia, Cavarzere, Paolo, Fava, Daniela, Parpagnoli, Maria, Bruzzi, Patrizia, Ibba, Anastasia, Calcaterra, Valeria, Mameli, Chiara, Grandone, Anna, Cherubini, Valentino, Assirelli, Valentina, Franchina, Francesca, Capalbo, Donatella, Mase, Raffaella Di, Tamaro, Gianluca, Cavasin, Julia, Munarin, Jessica, Russo, Gianni, Wasniewska, Malgorzata

المساهمون: A. Cassio, G. Marescotti, T. Aversa, M. Salerno, G. Tornese, M. Stancampiano, G. Tuli, M.F. Faienza, P. Cavarzere, D. Fava, M. Parpagnoli, P. Bruzzi, A. Ibba, V. Calcaterra, C. Mameli, A. Grandone, V. Cherubini, V. Assirelli, F. Franchina, D. Capalbo, R.D. Mase, G. Tamaro, J. Cavasin, J. Munarin, G. Russo, M. Wasniewska

مصطلحات موضوعية: boy, central precocious puberty, magnetic resonance imaging, Settore MED/38 - Pediatria Generale e Specialistica

الوصف: Context: There are only a few nationwide studies on boys with central precocious puberty (CPP) and the last Italian study is a case series of 45 boys that dates back to 2000. Objective: We aimed to evaluate the causes of CPP in boys diagnosed during the last 2 decades in Italy and the relative frequency of forms with associated central nervous system (CNS) abnormalities on magnetic resonance imaging (MRI) compared to idiopathic ones. Methods: We performed a national multicenter retrospective study collecting data from 193 otherwise normal healthy boys with a diagnosis of CPP. Based on MRI findings, the patients were divided into: Group 1, no CNS abnormalities; Group 2, mild abnormalities (incidental findings) unrelated to CPP; and Group 3, causal pathological CNS abnormalities. Results: The MRI findings show normal findings in 86%, mild abnormalities (incidental findings) in 8.3%, and causal pathological CNS abnormalities in 5.7% of the cases. In Group 3, we found a higher proportion of patients with chronological age at diagnosis < 7 years (P = .00001) and body mass index greater than +2 SDS (P < .01). Gonadotropin-releasing hormone analogue therapy was started in 183/193 subjects. The final height appeared in the range of the target height in all groups and in 9 patients in whom the therapy was not started. Conclusion: In our study on a large nationwide cohort of boys referred for precocious puberty signs, the percentage of forms associated with CNS abnormalities was one of the lowest reported in the literature.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/38308814; info:eu-repo/semantics/altIdentifier/wos/WOS:001158635900001; firstpage:1; lastpage:10; numberofpages:10; journal:THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM; https://hdl.handle.net/2434/1028349Test

الإتاحة: https://doi.org/10.1210/clinem/dgae035Test
https://hdl.handle.net/2434/1028349Test

المؤلفون: Corsello, Antonio, Milani, Gregorio Paolo, Picca, Marina, Buzzetti, Roberto, Carrozzo, Romeo, Gambino, Mirko, Chiaffoni, Giovanni, Marchisio, Paola, Mameli, Chiara

المساهمون: A. Corsello, G.P. Milani, M. Picca, R. Buzzetti, R. Carrozzo, M. Gambino, G. Chiaffoni, P. Marchisio, C. Mameli

مصطلحات موضوعية: Settore MED/38 - Pediatria Generale e Specialistica

الوصف: Background: Recurrent Upper Respiratory Tract Infections (R-URTIs) pose a significant challenge in pediatric healthcare, affecting both children and their families. This study aimed to investigate the prevalence, risk factors, and clinical implications of R-URTI in children aged 0-5 years. Methods: This observational study involved a sample of 483 children aged 0-5 years, focusing on establishing a practical and dynamic definition of R-URTI. Family pediatricians prospectively collected socio-demographic information, medical history, and recorded the occurrence of URTI episodes. Children were followed from recruitment until March 2021, predating the COVID-19 outbreak. Results: A substantial prevalence of R-URTIs was found, estimating it at 5-10% among this age group. To define R-URTI, a practical and dynamic criterion was proposed: children experiencing a minimum of four URTI episodes, each lasting four days or more, within a six-month period, with intervals of well-being in between. Conclusions: The study highlighted that specific risk factors for R-URTI were elusive, suggesting that this condition may affect children regardless of their family or clinical history. Moreover, the study's stratification by age group and times of observation facilitated patient-specific clinical decision-making. The proposed definition may represent a valuable tool for clinicians in diagnosing and addressing R-URTI cases.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/38365783; volume:50; issue:1; firstpage:1; lastpage:5; numberofpages:5; journal:THE ITALIAN JOURNAL OF PEDIATRICS; https://hdl.handle.net/2434/1030449Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85185394838

الإتاحة: https://doi.org/10.1186/s13052-024-01600-5Test
https://hdl.handle.net/2434/1030449Test

المؤلفون: Bonaventura, Eleonora, Alberti, Luisella, Lucchi, Simona, Cappelletti, Laura, Fazzone, Salvatore, Cattaneo, Elisa, Bellini, Matteo, Izzo, Giana, Parazzini, Cecilia, Bosetti, Alessandra, Di Profio, Elisabetta, Fiore, Giulia, Ferrario, Matilde, Mameli, Chiara, Sangiorgio, Arianna, Masnada, Silvia, Zuccotti, Gian Vincenzo, Veggiotti, Pierangelo, Spaccini, Luigina, Iascone, Maria, Verduci, Elvira, Cereda, Cristina, Tonduti, Davide

المصدر: Frontiers in Neurology ; volume 15 ; ISSN 1664-2295

مصطلحات موضوعية: Neurology (clinical), Neurology

الإتاحة: https://doi.org/10.3389/fneur.2024.1376447Test

المؤلفون: Mameli, Chiara, Triolo, Taylor M, Chiarelli, Francesco, Rewers, Marian, Zuccotti, Gianvincenzo, Simmons, Kimber M

المساهمون: Mameli, Chiara, Triolo, Taylor M, Chiarelli, Francesco, Rewers, Marian, Zuccotti, Gianvincenzo, Simmons, Kimber M

مصطلحات موضوعية: Children, Prevention, Screening, Teplizumab, Type 1 diabetes

الوصف: Type 1 diabetes (T1D) is a serious chronic autoimmune condition. Even though the root cause of T1D development has yet to be determined, enough is known about the natural history of T1D pathogenesis to allow study of interventions that may delay or even prevent the onset of hyperglycemia and clinical T1D. Primary prevention aims to prevent the onset of beta cell autoimmunity in asymptomatic people at high genetic risk for T1D. Secondary prevention strategies aim to preserve functional beta cells once autoimmunity is present, and tertiary prevention aims to initiate and extend partial remission of beta cell destruction after the clinical onset of T1D. The approval of teplizumab in the United States to delay the onset of clinical T1D marks an impressive milestone in diabetes care. This treatment opens the door to a paradigm shift in T1D care. People with T1D risk need to be identified early by measuring T1D related islet autoantibodies. Identifying people with T1D before they have symptoms will facilitate better understanding of pre-symptomatic T1D progression and T1D prevention strategies that may be effective.

العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:001008559700001; volume:193; firstpage:106792; numberofpages:11; journal:PHARMACOLOGICAL RESEARCH; https://hdl.handle.net/11564/820017Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85160247654; https://www.sciencedirect.com/science/article/pii/S1043661823001482?via=ihubTest

الإتاحة: https://doi.org/10.1016/j.phrs.2023.106792Test
https://hdl.handle.net/11564/820017Test
https://www.sciencedirect.com/science/article/pii/S1043661823001482?via=ihubTest

المؤلفون: Fiore, Giulia, Scapaticci, Serena, Neri, Costanza R, Azaryah, Hatim, Escudero-Marín, Mireia, Pascuzzi, Martina C, La Mendola, Alice, Mameli, Chiara, Chiarelli, Francesco, Campoy, Cristina, Zuccotti, Gianvincenzo, Verduci, Elvira

المساهمون: Fiore, Giulia, Scapaticci, Serena, Neri, Costanza R, Azaryah, Hatim, Escudero-Marín, Mireia, Pascuzzi, Martina C, La Mendola, Alice, Mameli, Chiara, Chiarelli, Francesco, Campoy, Cristina, Zuccotti, Gianvincenzo, Verduci, Elvira

مصطلحات موضوعية: abdominal obesity, breakfast habit, childhood obesity, children and adolescent, chrononutrition, meal frequency

الوصف: Context: Obesity has emerged as a global health issue for the pediatric population, increasing the need to investigate physiopathological aspects to prevent the appearance of its cardiometabolic complications. Chrononutrition is a field of research in nutritional sciences that investigates the health impact of 3 different dimensions of feeding behavior: regularity of meals, frequency, and timing of food intake. Objective: We carried out a systematic review and meta-analysis to investigate the association between chrononutrition in children and adolescents and the risk of overweight/obesity or a cluster of metabolic abnormalities related to glucose and lipid metabolism, blood pressure, and cardiovascular disease risk. Data extraction: A literature search was performed using PubMed, EMBASE, and The Cochrane Library for relevant articles published before August 2022. Data analysis: A total of 64 articles were included in the narrative synthesis (47 cross-sectional and 17 cohort studies), while 16 studies were included in the meta-analysis. Meta-analysis showed that non-daily breakfast consumers (≤6 d/wk) had a higher risk of overweight/obesity (odds ratio [OR], 1.45; 95% confidence interval [CI], 1.08-1.82] compared with daily breakfast eaters (7 d/wk). Similarly, irregular breakfast consumption (only 0-to-3 times/wk) increased the risk of abdominal obesity (waist-to-height ratio ≥ 0.5) compared with regular consumption (5-to-7 times/wk) (OR, 1.38; 95% CI, 1.26-1.49). There was evidence to suggest that a regular frequency of meal consumption (≥4 times/d) is preventive against overweight/obesity development compared with fewer meals (≤3 times/d) (OR, 0.83; 95% CI, 0.70-0.97). In the narrative synthesis, snacking habits showed controversial results, while food timing was the most understudied dimension. Conclusion: Overall, our data indicate a potential implication of chrononutrition in affecting pediatric metabolic health; however, the evidence of this association is limited and heterogeneous. Further prospective ...

وصف الملف: ELETTRONICO

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/37944081; numberofpages:46; journal:NUTRITION REVIEWS; https://hdl.handle.net/11564/820093Test

الإتاحة: https://doi.org/10.1093/nutrit/nuad122Test
https://hdl.handle.net/11564/820093Test

المؤلفون: Calcaterra, Valeria, Magenes, Vittoria Carlotta, Rossi, Virginia, Fabiano, Valentina, Mameli, Chiara, Zuccotti, Gian Vincenzo

المساهمون: V. Calcaterra, V.C. Magene, V. Rossi, V. Fabiano, C. Mameli, G.V. Zuccotti

مصطلحات موضوعية: Lipodystrophy, Leptin, Recombinant, Metreleptin, Metabolic unbalance, Children, Settore MED/38 - Pediatria Generale e Specialistica

الوصف: Lipodystrophy is a general definition containing different pathologies which, except for those observed in insulin-treated subjects falling outside the scope of this paper, are characterized by total or partial lack of body fat, that, according to the amount of missing adipose tissue, are divided in generalized or partial lipodystrophy. These diseases are characterized by leptin deficiency, which often leads to metabolic derangement, causing insulin resistance, dyslipidemia, and increasing cardiovascular risk. In this narrative review, we presentend the clinical presentation of different types of lipodystrophies and metabolic unbalances related to disease in children and adolescents, focusing on the main treatment options and the novel results from recombinant human leptin (metreleptin) therapy. Milestones in the management of lipodystrophy include lifestyle modification as diet and physical activity, paired with hypoglycemic drugs, insulin, hypolipidemic drugs, and other drugs with the aim of treating lipodystrophy complications. Metreleptin has been recently approved for pediatric patients with general lipodystrophy (GL)> 2 years of age and for children with partial lipodystrophy (PL)> 12 years of age not controlled with conventional therapies. New therapeutic strategies are currently being investigated, especially for patients with PL forms, specifically, liver-targeted therapies. Further studies are needed to achieve the most specific and precise treatment possible.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36566927; info:eu-repo/semantics/altIdentifier/wos/WOS:000917466700001; volume:187; firstpage:1; lastpage:10; numberofpages:10; journal:PHARMACOLOGICAL RESEARCH; https://hdl.handle.net/2434/949588Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85144873268

الإتاحة: https://doi.org/10.1016/j.phrs.2022.106629Test
https://hdl.handle.net/2434/949588Test